Newton Biocapital

DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.

Developer of pharmaceutical treatments designed to treat neurological disorders by repairing neurovascular function. The company's platform assists in restoring blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, traumatic brain injury, and brain cancer, as well as neurodegenerative diseases like Alzheimer's, enabling doctors to improve patient lives in a wide range of neurological disorders.

DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.

ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.

Synergia Medical SA, founded in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in the development of innovative neurostimulation medical devices. The company is focused on creating optoelectronic neurostimulators that utilize advanced materials, optical components, biosensors, and microelectronics. In particular, Synergia Medical aims to manufacture MRI-safe, implanted devices designed for treating drug-resistant epilepsy, with potential applications in other therapeutic areas. The company has achieved ISO13485 certification within a short period and has successfully developed and marketed an OEM external neurostimulator for motorized amputee prostheses. Supported by private investors and public research grants, Synergia Medical has rapidly expanded its team to include thirteen skilled professionals dedicated to advancing neurostimulation technology.

Dim3 SA specializes in the development and marketing of clinical expert platforms and medical devices aimed at improving clinical nutrition management. The company's offerings include Scorso, an application designed for the screening and monitoring of disease-related malnutrition; Nutrow, a decision support software that optimizes clinical nutrition; and Biocorder, a mobile clinical assistant. Founded in 2013 and based in Beaufays, Belgium, Dim3 addresses the critical issue of disease-related malnutrition, which poses significant health risks and incurs substantial costs in healthcare. By providing real-time assessments of patients' nutritional status and needs through scientific algorithms, Dim3 enables healthcare professionals to make timely and effective decisions that enhance patient outcomes while reducing overall healthcare expenses.